| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS
|
Moura, P.
|
|
|
128 |
S |
p.
|
article
|
| 2 |
ALLO HSCT IN OLDER PATIENTS: A QUESTION OF REAL PERSONALIZED MEDICINE
|
Blaise, D.
|
|
|
128 |
S |
p.
|
article
|
| 3 |
ANTIBODY-BASED THERAPY OF MDS
|
Brunner, A.
|
|
|
128 |
S |
p.
|
article
|
| 4 |
ATTEMPTS TO IMPROVE HYPOMETHYLATING AGENT-BASED REGIMENS: A TEN-YEAR EXPERIENCE
|
Ades, L.
|
|
|
128 |
S |
p.
|
article
|
| 5 |
Author Index
|
|
|
|
128 |
S |
p.
|
article
|
| 6 |
AUTO-INFLAMMATION AND VEXAS
|
Beck, D.
|
|
|
128 |
S |
p.
|
article
|
| 7 |
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES
|
Xu, Q.
|
|
|
128 |
S |
p.
|
article
|
| 8 |
BCL2 FAMILY INHIBITORS
|
Dinardo, C.
|
|
|
128 |
S |
p.
|
article
|
| 9 |
CCUS: CLINICAL PERSPECTIVE (HIGH-RISK CCUS)
|
Malcovati, L.
|
|
|
128 |
S |
p.
|
article
|
| 10 |
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES
|
Diaz-Mazkiaran, A.
|
|
|
128 |
S |
p.
|
article
|
| 11 |
CH ASSOCIATED DISEASES
|
Ebert, B.
|
|
|
128 |
S |
p.
|
article
|
| 12 |
CLINICAL MANAGEMENT OF CMML
|
Itzykson, R.
|
|
|
128 |
S |
p.
|
article
|
| 13 |
CLONAL HEMATOPOIESIS – FROM HEALTHY PERSONS TO LEUKEMIA SURVIVORS
|
Metzeler, K.
|
|
|
128 |
S |
p.
|
article
|
| 14 |
COMPREHENSIVE FLOW ANALYSIS OF PERIPHERAL BLOOD CELLS IN CMML DIAGNOSIS AND PROGNOSIS
|
Selimoglu-Buet, D.
|
|
|
128 |
S |
p.
|
article
|
| 15 |
CONTENTS
|
|
|
|
128 |
S |
p.
|
article
|
| 16 |
CONVERGENCE OF GENOMICS AND TRANSCRIPTOMIC PATTERNS IN MDS
|
Durmaz, A.
|
|
|
128 |
S |
p.
|
article
|
| 17 |
CTX-712, A NOVEL SPLICING INHIBITOR TARGETING MYELOID NEOPLASMS
|
Yoda, A.
|
|
|
128 |
S |
p.
|
article
|
| 18 |
CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY
|
Misidou, C.
|
|
|
128 |
S |
p.
|
article
|
| 19 |
CURRENT STATUS OF FLOW ANALYSIS OF MRD IN MDS
|
Van De Loosdrecht, A.
|
|
|
128 |
S |
p.
|
article
|
| 20 |
CURRENT STATUS OF MOLECULAR ANALYSIS OF MRD IN MDS
|
Duployez, N.
|
|
|
128 |
S |
p.
|
article
|
| 21 |
CURRENT TREATMENT OF MDS WITH DELETION 5Q
|
Sekeres, M.
|
|
|
128 |
S |
p.
|
article
|
| 22 |
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING
|
Nakagawa, M.
|
|
|
128 |
S |
p.
|
article
|
| 23 |
EARLY TRANSFUSION PATTERNS PREDICT OUTCOMES INDEPENDENTLY OF IPSS-M SCORE IN MYELODYSPLASTIC SYNDROMES
|
Creignou, M.
|
|
|
128 |
S |
p.
|
article
|
| 24 |
Editorial Board
|
|
|
|
128 |
S |
p.
|
article
|
| 25 |
EPIGENETIC DEREGULATION AND PROGRESSION
|
Figueroa, M.
|
|
|
128 |
S |
p.
|
article
|
| 26 |
EXCELLENT TRANSPLANT OUTCOMES WITH FLUDARABINE-TREOSULFAN (FT) REDUCED-TOXICITY CONDITIONING (RTC) IN COMBINATION WITH DUALT-CELL DEPLETION (TCD) IN MYELOABLATIVE CONDITIONING (MAC)-INELIGIBLE PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
|
Pasic, I.
|
|
|
128 |
S |
p.
|
article
|
| 27 |
FUNCTIONAL GENOMICS FOR NEW THERAPEUTIC APPROACHES IN MYELOID MALIGNANCIES
|
Tyner, J.
|
|
|
128 |
S |
p.
|
article
|
| 28 |
GENETIC ORIGINS AND CLONAL TRAJECTORIES IN PEDIATRIC MYELODYSPLASTIC SYNDROMES
|
Sahoo, S.
|
|
|
128 |
S |
p.
|
article
|
| 29 |
GEOGRAPHICAL AND SOCIOECONOMIC BARRIERS TO CARE FOR MYELODYSPLASTIC SYNDROMES
|
Afzal, A.
|
|
|
128 |
S |
p.
|
article
|
| 30 |
GERMLINE CHEK2 MUTATED MDS PATIENTS
|
Freiman, L.
|
|
|
128 |
S |
p.
|
article
|
| 31 |
GERMLINE DDX41 MUTATIONS : A SIGNIFICANT ENTITY WITHIN ADULT MDS/AML PATIENTS
|
Sébert, M.
|
|
|
128 |
S |
p.
|
article
|
| 32 |
GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY
|
Makishima, H.
|
|
|
128 |
S |
p.
|
article
|
| 33 |
HAPLO IN MDS: MORE THAN DONOR AVAILABILITY
|
Kroger, N.
|
|
|
128 |
S |
p.
|
article
|
| 34 |
HETEROCHROMATIN CHANGES IN HSCS FROM CMML PATIENTS CONFER SENSITIVITY TO THE COMBINATION OF G9A/GLP INHIBITORS AND DNA HYPOMETHYLATING AGENTS VIA DEREPRESSION OF RETROELEMENTS
|
Hidaoui, D.
|
|
|
128 |
S |
p.
|
article
|
| 35 |
MACROH2A1.1 SITS AT THE INTERPLAY BETWEEN EPIGENETICS AND INFLAMMATION OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES
|
Giallongo, C.
|
|
|
128 |
S |
p.
|
article
|
| 36 |
MDS AND AUTO-IMMUNITY
|
Dezern, A.
|
|
|
128 |
S |
p.
|
article
|
| 37 |
MDS PATIENT INFORMATION AND HEALTH LITERACY
|
Mancini, J.
|
|
|
128 |
S |
p.
|
article
|
| 38 |
OVERVIEW OF PEDIATRIC MDS AND JMML
|
Flotho, C.
|
|
|
128 |
S |
p.
|
article
|
| 39 |
PATHOPHYSIOLOGY OF PROGRESSION OF FANCONI ANEMIA TO MDS/AML
|
Soulier, J.
|
|
|
128 |
S |
p.
|
article
|
| 40 |
PATIENT AVATARS TO GUIDE CLINICAL TRIALS IN CMML
|
Padron, E.
|
|
|
128 |
S |
p.
|
article
|
| 41 |
PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
|
Zeidan, A.
|
|
|
128 |
S |
p.
|
article
|
| 42 |
POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS
|
Nannya, Y.
|
|
|
128 |
S |
p.
|
article
|
| 43 |
PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY
|
Duarte, F.B.
|
|
|
128 |
S |
p.
|
article
|
| 44 |
Publication Information Page
|
|
|
|
128 |
S |
p.
|
article
|
| 45 |
PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML
|
Shastri, A.
|
|
|
128 |
S |
p.
|
article
|
| 46 |
QOL
|
Efficace, F.
|
|
|
128 |
S |
p.
|
article
|
| 47 |
SF3B1 AND MDS-RS: THE BIOLOGICAL PERSPECTIVE
|
Fontenay, M.
|
|
|
128 |
S |
p.
|
article
|
| 48 |
SHWACHMAN-DIAMOND SYNDROME AND TELOMEROPATHY
|
Shimamura, A.
|
|
|
128 |
S |
p.
|
article
|
| 49 |
SINGLE CELL DATA
|
Ganan-Gomez, I.
|
|
|
128 |
S |
p.
|
article
|
| 50 |
SRSF2 AND TET2 CO-MUTATION SKEW HAEMATOPOIESIS IN MYELODYSPLASTIC NEOPLASMS (MDNS)
|
Liang, Y.
|
|
|
128 |
S |
p.
|
article
|
| 51 |
TARGETING DYSERYTHROPOIESIS IN CLINICAL PRACTICE
|
Hellstrom-Lindberg, E.
|
|
|
128 |
S |
p.
|
article
|
| 52 |
TARGETING RNA EPIGENETICS TO PREDICT AND OVERCOME DRUG RESISTANCE IN MDS AND AML
|
Cheng, J.
|
|
|
128 |
S |
p.
|
article
|
| 53 |
TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
|
Philippe, C.
|
|
|
128 |
S |
p.
|
article
|
| 54 |
TARGETING THE SPLICEOSOME
|
Abdel-Wahab, O.
|
|
|
128 |
S |
p.
|
article
|
| 55 |
THE NEW MOLECULAR IPSS
|
Bernard, E.
|
|
|
128 |
S |
p.
|
article
|
| 56 |
THE NLRC4 INFLAMMASOME DRIVES MYELODYSPLASTIC SYNDROME BY LINKING EPIGENETIC REPROGRAMMING AND INNATE IMMUNE SIGNALING
|
Chen, C.
|
|
|
128 |
S |
p.
|
article
|
| 57 |
THERAPEUTIC TARGETING OF INFLAMMATION
|
Platzbecker, U.
|
|
|
128 |
S |
p.
|
article
|
| 58 |
THERAPEUTIC TARGETS IN RAS-MEDIATED PROLIFERATIVE CMML
|
Patnaik, M.
|
|
|
128 |
S |
p.
|
article
|
| 59 |
THERAPIES OF ANEMIA (EXCLUDING MDS-RS TREATMENT)
|
Santini, V.
|
|
|
128 |
S |
p.
|
article
|
| 60 |
THERAPY OF TP53 MUT MDS
|
Sallman, D.
|
|
|
128 |
S |
p.
|
article
|
| 61 |
Title Page
|
|
|
|
128 |
S |
p.
|
article
|
| 62 |
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS
|
Kolomansky, A.
|
|
|
128 |
S |
p.
|
article
|
| 63 |
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLINE PREDISPOSITION
|
Kanagal-Shamanna, R.
|
|
|
128 |
S |
p.
|
article
|
| 64 |
Topic: AS01-Diagnosis/AS01a-Cytomorphology: DIAGNOSTIC CHALLENGE BETWEEN WHO AND ICC CLASSIFICATION
|
Kim, H.
|
|
|
128 |
S |
p.
|
article
|
| 65 |
Topic: AS01-Diagnosis/AS01a-Cytomorphology: NON-INVASIVE WEB-BASED DIAGNOSTIC ALGORITHM FOR MDS – MODEL PERFORMANCE AND VALIDATION
|
Polakow, A.
|
|
|
128 |
S |
p.
|
article
|
| 66 |
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WITH RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS
|
Raddi, M.G.
|
|
|
128 |
S |
p.
|
article
|
| 67 |
Topic: AS01-Diagnosis/AS01b-Flow cytometry: FLOW CYTOMETRIC SCREENING IN PERIPHERAL BLOOD TO GUIDE THE DIAGNOSTIC ALGORITHM IN MDS
|
Oelschlaegel, U.
|
|
|
128 |
S |
p.
|
article
|
| 68 |
Topic: AS01-Diagnosis/AS01b-Flow cytometry: IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION
|
Souto, E.
|
|
|
128 |
S |
p.
|
article
|
| 69 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS/MDS ITALIAN EXPERIENCE
|
Gurnari, C.
|
|
|
128 |
S |
p.
|
article
|
| 70 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): ANALYSIS OF 1,754 BONE MARROW KARYOTYPES IN MYELOID NEOPLASMS
|
Sampaio, L.
|
|
|
128 |
S |
p.
|
article
|
| 71 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): APPLICATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-M) MODEL IN SOUTH-AMERICAN MDS PATIENTS: A STUDY FROM ARGENTINA AND URUGUAY
|
Lincango, M.
|
|
|
128 |
S |
p.
|
article
|
| 72 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): BASIC BLOOD COUNT AND FLOW CYTOMETRY PARAMETERS CAN PREDICT THE PRESENCE OF A MUTATION IN NON-DIAGNOSTIC BONE MARROW SAMPLES
|
Cargo, C.
|
|
|
128 |
S |
p.
|
article
|
| 73 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): CLINICO-GENETIC AND PROGNOSTIC ANALYSES OF 716 PATIENTS WITH PRIMARY MDS AND MDS/AML BASED ON THE 2022 INTERNATIONAL CONSENSUS CLASSIFICATION
|
Ni, S.-C.
|
|
|
128 |
S |
p.
|
article
|
| 74 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENETIC IDENTIFICATION BY NGS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
|
Lee, A.-J.
|
|
|
128 |
S |
p.
|
article
|
| 75 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
|
Bernard, E.
|
|
|
128 |
S |
p.
|
article
|
| 76 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): INITIALLY AND NEWLY ACQUIRED TP53 MUTATIONS IN PATIENTS WITH MDS WITH DEL(5Q) WITH/WITHOUT LENALIDOMIDE
|
Ganster, C.
|
|
|
128 |
S |
p.
|
article
|
| 77 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MOLECULAR PROFILE OF MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS. REAL WORLD DATA FROM ARGENTINA AND URUGUAY
|
Lincango, M.
|
|
|
128 |
S |
p.
|
article
|
| 78 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)
|
Zemanova, Z.
|
|
|
128 |
S |
p.
|
article
|
| 79 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): PATHOGENIC VARIANTS RELATED TO HEMATOLOGIC MALIGNANCIES CONTRIBUTE TO THE DIFFERENTIAL DIAGNOSIS OF CYTOPENIAS
|
Papalexandri, A.
|
|
|
128 |
S |
p.
|
article
|
| 80 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): PRATICAL USE OF MONOCYTE SUBSET BY FLOW CYTOMETRY AND SEQUENCING IN DIAGNOSIS AND PROGNOSIS OF CLINICAL RELEVANT MONOCYTOSIS
|
Podvin, B.
|
|
|
128 |
S |
p.
|
article
|
| 81 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): REAL-WORLD LABORATORY PRACTICE PATTERNS ON NEXT-GENERATION-SEQUENCING (NGS) TECHNOLOGY IN LATIN AMERICA
|
Belli, C.
|
|
|
128 |
S |
p.
|
article
|
| 82 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): UMBRELLA PROJECT: UNIFIED PLATFORM FOR A BETTER INTEGRAL EVALUATION OF MYELODYSPLASTIC SYNDROMES IN SPAIN
|
Solas, T. Jiménez
|
|
|
128 |
S |
p.
|
article
|
| 83 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): VEXAS SYNDROME IDENTIFIED ON SOMATIC NGS PANEL IN A FRACTION OF PATIENTS OF MYELODYSPLASTIC SYNDROME AND MYELODYSPLASIA/MYELOPROLIFERATIVE NEOPLASMS WITH AUTOIMMUNE AND INFLAMMATORY DISORDERS
|
Sadawarte, S.
|
|
|
128 |
S |
p.
|
article
|
| 84 |
Topic: AS02-Epidemiology: CHIP AND INCIDENTAL ANAEMIA IN PATIENTS REFERRED TO SYDNEY GERIATRIC CLINICS FOR FRAILTY ASSESSMENT – A PROSPECTIVE STUDY
|
Ma, D.
|
|
|
128 |
S |
p.
|
article
|
| 85 |
Topic: AS02-Epidemiology: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A CHILEAN HEMATOLOGICAL REFERENCE CENTER
|
Valladares, X.
|
|
|
128 |
S |
p.
|
article
|
| 86 |
Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY
|
Mathur, S.
|
|
|
128 |
S |
p.
|
article
|
| 87 |
Topic: AS02-Epidemiology: TET2 CLONAL HEMATOPOIESIS MUTATIONS ARE ENRICHED AMONG RECIPIENTS OF SOLID-ORGAN TRANSPLANTS
|
Silver, A.
|
|
|
128 |
S |
p.
|
article
|
| 88 |
Topic: AS02-Epidemiology: THE EPIDEMIOLOGY OF MYELODYSPLASTIC SYNDROME (MDS) FROM ARMENIA, A RESOURCE-LIMITED COUNTRY
|
Sevoyan, A.
|
|
|
128 |
S |
p.
|
article
|
| 89 |
Topic: AS02-Epidemiology: TP53 MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA. REAL WORLD DATA FROM LATIN AMERICAN MDS GROUP (GLAM)
|
Boada, M.
|
|
|
128 |
S |
p.
|
article
|
| 90 |
Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ALTERNATIVE DOSING SCHEDULES OF AZACITIDINE: A REAL-WORLD COMPARATIVE STUDY ACROSS SOUTH AMERICAN CENTERS
|
Castelo, L.
|
|
|
128 |
S |
p.
|
article
|
| 91 |
Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ?
|
Santini, V.
|
|
|
128 |
S |
p.
|
article
|
| 92 |
Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes: IMPLEMENTATION AND USE OF ELECTRONIC PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS
|
Stauder, R.
|
|
|
128 |
S |
p.
|
article
|
| 93 |
Topic: AS03-Health Economics & Outcome Research/AS03c-Efficacy outcome measures: ONLINE EDUCATION IMPROVED CLINICIAN KNOWLEDGE RELATED TO TARGETING CD47 FOR THE TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA
|
Bomba, S.
|
|
|
128 |
S |
p.
|
article
|
| 94 |
Topic: AS03-Health Economics & Outcome Research/AS03c-Efficacy outcome measures: STATINS IMPROVE OVERALL- AND LEUKEMIA FREE- SURVIVAL FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES; A RETROSPECTIVE SEER- MEDICARE ANALYSIS
|
Afzal, A.
|
|
|
128 |
S |
p.
|
article
|
| 95 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: CALPROTECTIN (S100A8/A9) EFFECTS ON HEALTHY CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE AMPLIFIED IN CHRONIC MYELOID MALIGNANCIES
|
Marchand, V.
|
|
|
128 |
S |
p.
|
article
|
| 96 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA
|
Okuda, R.
|
|
|
128 |
S |
p.
|
article
|
| 97 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: MULTIOMIC ANALYSIS OF CHIP BONE MARROW HEMATOPOIETIC STEM/PROGENITOR CELLS REVEALS POTENTIAL EARLY STAGE OF MALIGNANCY
|
Van Der Garde, M.
|
|
|
128 |
S |
p.
|
article
|
| 98 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: ULTRA-LOW INPUT SEQUENCING TO IDENTIFIES TRANSPLANT RESISTANT STEM CELLS IN MYELODYSPLASTIC SYNDROMES
|
Kroger, B.
|
|
|
128 |
S |
p.
|
article
|
| 99 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: USING PU.1 AND JDP2 TRANSCRIPTION FACTOR EXPRESSION IN MYELODYSPLASTIC SYNDROMES TO PREDICT TREATMENT RESPONSE AND LEUKEMIA TRANSFORMATION
|
Boasman, K.
|
|
|
128 |
S |
p.
|
article
|
| 100 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: ANALYSIS OF CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES USING DNA-SINGLE CELL ANALYSIS
|
Acha, P.
|
|
|
128 |
S |
p.
|
article
|
| 101 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
|
Calvete, O.
|
|
|
128 |
S |
p.
|
article
|
| 102 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: IMPROVING THE CLONAL EVOLUTION MODEL: THE CASE OF CMML
|
Laplane, L.
|
|
|
128 |
S |
p.
|
article
|
| 103 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: INTEGRATED ANALYSIS OF MDS-OMICS INFORMS ON DRUG RESPONSE PROFILES
|
Durmaz, A.
|
|
|
128 |
S |
p.
|
article
|
| 104 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONGITUDINAL PREVALENCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN BREAST AND OVARIAN CANCER PATIENTS PRIOR AND AFTER RECEIVING CYTOTOXIC TREATMENT
|
Calvete, O.
|
|
|
128 |
S |
p.
|
article
|
| 105 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
|
Castelló, S.M. Toribio
|
|
|
128 |
S |
p.
|
article
|
| 106 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO DNA METHYLATION INHIBITOR THERAPY
|
Campillo-Marcos, I.
|
|
|
128 |
S |
p.
|
article
|
| 107 |
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): CORRECTING DYSREGULATED IRON METABOLISM IN A MURINE MODEL OF MDS
|
Vilcassim, S.
|
|
|
128 |
S |
p.
|
article
|
| 108 |
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): EGCG IMPROVES INEFFECTIVE HEMATOPOIESIS IN A MOUSE MODEL OF MYELODYSPLASTIC SYNDROME
|
Della Via, F.
|
|
|
128 |
S |
p.
|
article
|
| 109 |
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGULATING MITOCHONDRIA OXIDATIVE METABOLIC PATHWAY
|
Dong, B.
|
|
|
128 |
S |
p.
|
article
|
| 110 |
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE
|
Schmitt, N.
|
|
|
128 |
S |
p.
|
article
|
| 111 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: A NOVEL STOP-GAIN SNV IN REV1 GENE IN MYELODYSPLASTIC NEOPLASM
|
Oliveira, R.
|
|
|
128 |
S |
p.
|
article
|
| 112 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8
|
Castelló, S.M. Toribio
|
|
|
128 |
S |
p.
|
article
|
| 113 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: SEX DETERMINES DIFFERENTIAL GENOMIC PROFILES IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) INVOLVING UNDERREPRESENTATION OF SRSF2 GENE MUTATION
|
Calvo, X.
|
|
|
128 |
S |
p.
|
article
|
| 114 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB
|
Erlacher, M.
|
|
|
128 |
S |
p.
|
article
|
| 115 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
|
Montoro, M.J.
|
|
|
128 |
S |
p.
|
article
|
| 116 |
Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION
|
Rombaut, D.
|
|
|
128 |
S |
p.
|
article
|
| 117 |
Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: EXPLORING GENETIC DEPENDENCIES IN SPLICEOSOME MUTATED MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA
|
Mutch, A.
|
|
|
128 |
S |
p.
|
article
|
| 118 |
Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: EXPLORING IMMUNE ACTIVATION IN MYELOID MALIGNANCIES
|
Briggs, R.
|
|
|
128 |
S |
p.
|
article
|
| 119 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CHARACTERIZATION OF THE TRANSCRIPTIONAL ALTERATIONS OF PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROME
|
Zufiaurre, N. Berastegui
|
|
|
128 |
S |
p.
|
article
|
| 120 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION
|
Imanci, A.
|
|
|
128 |
S |
p.
|
article
|
| 121 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: HEMATOPOIETIC STEM CELLS OF LOWER-RISK MDS PATIENTS WITH RAPID PROGRESSION SHOW QUIESCENT-LIKE CELL STATE SIMILAR TO THAT OF HIGHER-RISK MDS CELLS
|
Kaisrlikova, M.
|
|
|
128 |
S |
p.
|
article
|
| 122 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: KENNEDY’S DISEASE AND MYELODISPLASTIC SYNDROME: A POSSIBLE NEW ENTITY IN MYELOID NEOPLASM GERMLINE PREDISPOSITION. A CASE REPORT
|
Piccioni, A.L.
|
|
|
128 |
S |
p.
|
article
|
| 123 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATION-SPECIFIC HSPC ENRICHMENT PATTERNS UNDERLIE PROGNOSTICALLY SIGNIFICANT TRANSCRIPTOMIC SUBGROUPS OF MDS PATIENTS
|
Sakuma, M.
|
|
|
128 |
S |
p.
|
article
|
| 124 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: SURFACE EPITOPE AND TRANSCRIPTOME ANALYSIS OF BONE MARROW IN MYELODYSPLASTIC SYNDROME (MDS) USING CITE-SEQ
|
Kodgule, R.
|
|
|
128 |
S |
p.
|
article
|
| 125 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE GENE EXPRESSION PROFILE OF GENES BELONGING TO TRANSFORMING GROWTH FACTOR-B PATHWAY IS DEREGULATED IN SF3B1 MUTATED LOW-RISK MDS PATIENTS
|
Fabiani, E.
|
|
|
128 |
S |
p.
|
article
|
| 126 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: H19 NON-CODING RNA (LNCRNA) ACTS AS A TUMOR SUPPRESSOR IN MYELODYSPLASTIC NEOPLASM (MDS)
|
Borges, D.
|
|
|
128 |
S |
p.
|
article
|
| 127 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: METHYLATION PROFILE OF SINGLE-STRANDED AND DOUBLE-STRANDED REPAIR GENES IN PATIENTS WITH MDS
|
Filho, R.
|
|
|
128 |
S |
p.
|
article
|
| 128 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: SINGLE CELL PROTEOMICS IDENTIFIES DISTINCT EPIGENETIC PERTURBATIONS AND BIOMARKERS TO PREDICT RESPONSIVENESS TO AZACITIDINE IN MDS AND AML
|
Tien, F.M.
|
|
|
128 |
S |
p.
|
article
|
| 129 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: THE KEAP1-NRF2 REDOX PATHWAY CONTROLS THE SENSITIVITY OF MDS/AML CELLS TO AZACYTIDINE
|
Pimková, K.
|
|
|
128 |
S |
p.
|
article
|
| 130 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ABERRANT IMMUNE LANDSCAPE IN BONE MARROW OF HIGH-RISK MYELODYSPLASTIC SYNDROME PATIENTS
|
Rai, R.
|
|
|
128 |
S |
p.
|
article
|
| 131 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ALTERED DEVELOPMENTAL PATHWAYS OF INNATE LYMPHOID CELLS IN MYELODYSPLASTIC SYNDROMES CORRELATE DISEASE PROGNOSIS AND RESPONSE TO THERAPY
|
Calvi, M.
|
|
|
128 |
S |
p.
|
article
|
| 132 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: AZACYTIDINE TREATMENT UNDERSCORES ITS HYPOMETHYLATING EFFECT IN HUMAN LEYKOCYTE ANTIGEN G (HLA-G) GENE PROMOTER REGION OF HIGH-RISK (HR)-MDS PATIENTS
|
Chatzilygeroudi, T.
|
|
|
128 |
S |
p.
|
article
|
| 133 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS
|
Yordi, A. Molero
|
|
|
128 |
S |
p.
|
article
|
| 134 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS
|
Yordi, A. Molero
|
|
|
128 |
S |
p.
|
article
|
| 135 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CORRELATIONS BETWEEN IMMUNOLOGICAL AND MUTATIONAL PROFILE IN MYELODYSPLASTIC SYNDROME
|
Cristiano, A.
|
|
|
128 |
S |
p.
|
article
|
| 136 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CXCL8 SECRETED BY IMMATURE GRANULOCYTES INHIBITS WILD-TYPE STEM AND PROGENITOR CELL EXPANSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
|
Deschamps, P.
|
|
|
128 |
S |
p.
|
article
|
| 137 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HETEROGENEITY OF BONE MARROW INFLAMMATION STATES IN LR-MDS
|
Schneider, M.
|
|
|
128 |
S |
p.
|
article
|
| 138 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY
|
Mendonca, P.
|
|
|
128 |
S |
p.
|
article
|
| 139 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: MICROTUBULE POLYMERIZATION INHIBITION PROVIDES A STRATEGY FOR TARGETING THE INFLAMMATORY MICROENVIRONMENT
|
Bueno, M.
|
|
|
128 |
S |
p.
|
article
|
| 140 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: NEPHROTIC SYNDROME IN MDS: A CASE REPORT AND REVIEW OF THE LITERATURE
|
Davis, W.
|
|
|
128 |
S |
p.
|
article
|
| 141 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION
|
Oster, H.
|
|
|
128 |
S |
p.
|
article
|
| 142 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: STAT3 MUTATIONS IMPACT ON MDS ASSOCIATION IN PATIENTS WITH LGL LEUKEMIA (LGLL)
|
Calabretto, G.
|
|
|
128 |
S |
p.
|
article
|
| 143 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS
|
Tasis, A.
|
|
|
128 |
S |
p.
|
article
|
| 144 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: GENE EXPRESSION PROFILE OF HUMAN MESENCHYMAL STROMAL CELLS FROM MYELODYSPLASTIC SYNDROME PATIENTS AND HEALTHY CONTROLS
|
Boada, M.
|
|
|
128 |
S |
p.
|
article
|
| 145 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES THROUGH IGFBP2
|
Marchand, V.
|
|
|
128 |
S |
p.
|
article
|
| 146 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION OF MESENCHYMAL STROMAL CELLS FROM INDIVIDUALS WITH CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) REVEALS EARLY CHANGES IN THE BONE MARROW NICHE
|
Figueredo, A. Navarro
|
|
|
128 |
S |
p.
|
article
|
| 147 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
|
Pfeilstöcker, M.
|
|
|
128 |
S |
p.
|
article
|
| 148 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: APPLICABILITY OF IPSS-M IN MYELODYSPLASTIC SYNDROMES ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
|
Gurnari, C.
|
|
|
128 |
S |
p.
|
article
|
| 149 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
|
Kuendgen, A.
|
|
|
128 |
S |
p.
|
article
|
| 150 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF MRD-MARKERS USING MUTATION-SPECIFIC DDPCR IN BONE MARROW AND PERIPHERAL BLOOD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS
|
Lindholm, C.
|
|
|
128 |
S |
p.
|
article
|
| 151 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
|
Schulz, F.
|
|
|
128 |
S |
p.
|
article
|
| 152 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: GENOMIC DETERMINANTS OF DYSMYELOPOIESIS AND EVALUATION OF ITS PROGNOSTIC IMPACT IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
|
Calvo, X.
|
|
|
128 |
S |
p.
|
article
|
| 153 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: HIGH BM PLASMA S100A8/A9 IS ASSOCIATED WITH A PERTURBED MICROENVIRONMENT AND POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROMES
|
Wang, Y.-H.
|
|
|
128 |
S |
p.
|
article
|
| 154 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP
|
Amer, N.
|
|
|
128 |
S |
p.
|
article
|
| 155 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF IPSS-M IMPLEMENTATION IN REAL-LIFE CLINICAL PRACTICE
|
Zamanillo, I.
|
|
|
128 |
S |
p.
|
article
|
| 156 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
|
Kasprzak, A.
|
|
|
128 |
S |
p.
|
article
|
| 157 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RISK ASSESSMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
|
Azoulay, D.
|
|
|
128 |
S |
p.
|
article
|
| 158 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
|
Nachtkamp, K.
|
|
|
128 |
S |
p.
|
article
|
| 159 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: SOMATIC TP53 SINGLE NUCLEOTIDE VARIANTS, INDELS AND COPY NUMBER ALTERATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
|
Gurney, M.
|
|
|
128 |
S |
p.
|
article
|
| 160 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: STUDY OF LEPTIN AND ADIPONECTIN POLYMORPHISMS IN MYELODYSPLASTIC SYNDROME
|
Mendonca, P.
|
|
|
128 |
S |
p.
|
article
|
| 161 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: TET2 MUTATIONAL STATUS AFFECTS MYELODYSPLASTIC SYNDROME EVOLUTION TO CHRONIC MYELOMONOCYTIC LEUKEMIA
|
Quang, V. Tran
|
|
|
128 |
S |
p.
|
article
|
| 162 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS
|
Ryabov, V.
|
|
|
128 |
S |
p.
|
article
|
| 163 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
|
Kotsianidis, I.
|
|
|
128 |
S |
p.
|
article
|
| 164 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
|
Dimitriou, D.
|
|
|
128 |
S |
p.
|
article
|
| 165 |
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORATORY PARAMETERS
|
Maciel, R. Oliviera
|
|
|
128 |
S |
p.
|
article
|
| 166 |
Topic: AS09-Quality of life-Disease experiences: EXPLORING UNMET NEEDS OF MDS PATIENTS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
|
Crisà, E.
|
|
|
128 |
S |
p.
|
article
|
| 167 |
Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS
|
Buckstein, R.
|
|
|
128 |
S |
p.
|
article
|
| 168 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: CLINICAL AND CARDIOVASCULAR RISK ASSESSMENT OF SUBJECTS WITH JAK2-V617F CLONAL HEMATOPOIESIS
|
Garrido, S.
|
|
|
128 |
S |
p.
|
article
|
| 169 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIENTS
|
González, A. Pérez
|
|
|
128 |
S |
p.
|
article
|
| 170 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: RARE GENETIC DETERMINANTS OF CLONAL HEMATOPOIESIS AND PROGRESSION TO HEMATOLOGIC MALIGNANCIES
|
Liu, J.
|
|
|
128 |
S |
p.
|
article
|
| 171 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: REAL WORLD APPLICABILITY OF THE CLONAL HEMATOPOEISIS RISK SCORE (CHRS): A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY
|
Madanat, Y.
|
|
|
128 |
S |
p.
|
article
|
| 172 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: THE IMPACT OF CHIP ON CHEMOTHERAPY-RELATED OUTCOMES AND CLONAL DYNAMICS IN OLDER LYMPHOMA PATIENTS
|
Buckstein, R.
|
|
|
128 |
S |
p.
|
article
|
| 173 |
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: T-LGL A FRIEND OR THE FOE IN CLONAL HEMATOPOIESIS?: IMPLICATIONS FOR IMMUNOTHERAPY/IMMUNOSUPPRESSION
|
Kawashima, N.
|
|
|
128 |
S |
p.
|
article
|
| 174 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS
|
Gurnari, C.
|
|
|
128 |
S |
p.
|
article
|
| 175 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
|
Santiago, M.
|
|
|
128 |
S |
p.
|
article
|
| 176 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: HIGH PREVALENCE OF IDIOPATHIC DYPSLASIA OF UNDETERMINED SIGNIFICANCE (IDUS) AND CLONAL HEMATOPOIESIS OF INDETEMINATE POTENTIAL (CHIP) AMONG RELATIVES OF HEMATOLOGIC NEOPLASMS WITH GERMLINE PREDISPOSITION PATIENTS
|
Novoa, S.
|
|
|
128 |
S |
p.
|
article
|
| 177 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: NEUTROPHIL ACTIVATION AND PLATELET AGGREGATION IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
|
Lindhauer, N.S.
|
|
|
128 |
S |
p.
|
article
|
| 178 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: SECONDARY FINDINGS IN EXOME SEQUENCING IN 240 EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES WITHOUT PREVIOUS DISORDER
|
Montoro, M.J.
|
|
|
128 |
S |
p.
|
article
|
| 179 |
Topic: AS07-Singular Entities/Subtypes/AS07d-MDS with ring sideroblasts: COEXISTENCE OF SF3B1 AND JAK2 EXON 25 MUTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME PROGRESSING TO INV(3)(Q21Q26) ACUTE MYELOID LEUKEMIA
|
Apostolidou, E.
|
|
|
128 |
S |
p.
|
article
|
| 180 |
Topic: AS07-Singular Entities/Subtypes/AS07d-MDS with ring sideroblasts: MYELOID NEOPLASMS WITH SF3B1 MUTATION: A BRAZILIAN COHORT
|
Fernandes, L.
|
|
|
128 |
S |
p.
|
article
|
| 181 |
Topic: AS07-Singular Entities/Subtypes/AS07d-MDS with ring sideroblasts: SF3B1 MUTATIONS AND THEIR IMPACT ON CELLULAR BIOENERGETICS IN MYELODYSPLASTIC SYNDROMES
|
Hrustincova, A.
|
|
|
128 |
S |
p.
|
article
|
| 182 |
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): CLINICO-BIOLOGICAL CHARACTERISTICS AND OUTCOME OF 313 CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS INCLUDING 104 FORMERLY REFERRED TO AS OLIGOMONOCYTIC
|
Castaño-Díez, S.
|
|
|
128 |
S |
p.
|
article
|
| 183 |
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
|
Acha, P.
|
|
|
128 |
S |
p.
|
article
|
| 184 |
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): INCORPORATION OF MOLECULAR PROFILE TO A COHORT OF ALLOGRAFTED MYELOMONOCITIC LEUKEMIA PATIENTS. UNICENTRIC EXPERIENCE
|
Pita, A. Avendaño
|
|
|
128 |
S |
p.
|
article
|
| 185 |
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): TET2/SRSF2 STATUS AND THROMBOSIS ARE RELEVANT FOR PROGNOSIS IN CHRONIC MYELOMONOCYTIC LEUKEMIA –DATA FROM A POPULATION-BASED STUDY OF 155 PATIENTS
|
Kynning, M. Kjellander
|
|
|
128 |
S |
p.
|
article
|
| 186 |
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT
|
Kynning, M. Kjellander
|
|
|
128 |
S |
p.
|
article
|
| 187 |
Topic: AS07-Singular Entities/Subtypes/AS07f-MDS with deletion 5q: IMPORTANCE OF CYTOGENETICS MONITORING IN CLINICAL FOLLOW-UP
|
Minete, N.
|
|
|
128 |
S |
p.
|
article
|
| 188 |
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING
|
Zeidan, A.
|
|
|
128 |
S |
p.
|
article
|
| 189 |
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: SALVAGE VENETOCLAX COMBINATION THERAPY IN PATIENTS WITH AML TRANSFORMATION AFTER AZACITIDINE THERAPY FAILURE FOR HIGH-RISK MDS – SINGLE-CENTER EXPERIENCE
|
Minarik, L.
|
|
|
128 |
S |
p.
|
article
|
| 190 |
Topic: AS08-Treatment/AS08a-Current treatment options - Higher risk MDS: SINGLE-CENTER EXPERIENCE OF AZACITIDINE-VENETOCLAX IN SECONDARY ACUTE MYELOID LEUKEMIA (AML), ARISING FROM MYELODYSPLASTIC SYNDROME (MDS), MYELOPROLIFERATIVE NEOPLASM (MPN) OR MDS/MPN OVERLAP
|
Halim, N.A. Abdul
|
|
|
128 |
S |
p.
|
article
|
| 191 |
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP – GLAM
|
Iastrebner, M.
|
|
|
128 |
S |
p.
|
article
|
| 192 |
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT FOR PATIENTS WITH LOWER RISK MDS ADMITTED TO THE HEMATOLOGY DEPARTMENT OF THE COLENTINA CLINICAL HOSPITAL - DATA FROM CLINICAL EXPERIENCE
|
Georgescu, D.
|
|
|
128 |
S |
p.
|
article
|
| 193 |
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN LOWER-RISK MDS TRANSFUSION-DEPENDENT PATIENTS; A SINGLE-CENTRE EXPERIENCE
|
Papalexandri, A.
|
|
|
128 |
S |
p.
|
article
|
| 194 |
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE
|
Bouchla, A.
|
|
|
128 |
S |
p.
|
article
|
| 195 |
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
|
Garcia-Manero, G.
|
|
|
128 |
S |
p.
|
article
|
| 196 |
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
|
Jonasova, A.
|
|
|
128 |
S |
p.
|
article
|
| 197 |
Topic: AS08-Treatment/AS08d-New developments – Preclinical studies: DEVELOPMENT OF APTAMERS AS THERAPY FOR CONGENITAL NEUTROPENIA DISEASES
|
Cayuela, M.
|
|
|
128 |
S |
p.
|
article
|
| 198 |
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
|
Savona, M.
|
|
|
128 |
S |
p.
|
article
|
| 199 |
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: PEVAZ: A PHASE II STUDY OF PEVONEDISTAT AND AZACITIDINE IN MDS AND MDS/MPN PATIENTS RELAPSED OR REFRACTORY TO DNMT INHIBITION (DNMTI)
|
Watts, J.
|
|
|
128 |
S |
p.
|
article
|
| 200 |
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: PHASE 2 STUDY OF ORAL DECITABINE AND CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
|
Zeidan, A.
|
|
|
128 |
S |
p.
|
article
|
| 201 |
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
|
Garcia-Manero, G.
|
|
|
128 |
S |
p.
|
article
|
| 202 |
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
|
Dezern, A.
|
|
|
128 |
S |
p.
|
article
|
| 203 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS WHO UNDERGO MATCHED UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
|
Sayyed, A.
|
|
|
128 |
S |
p.
|
article
|
| 204 |
Topic: AS08-Treatment/AS08i-observational studies: ALLOGENEIC ADOPTIVE CELLULAR IMMUNOTHERAPY FOR MYELODYSPLASTIC SYNDROME AND ITS EFFECT ON TRISOMY OF CHROMOSOME 8
|
Liu, H.
|
|
|
128 |
S |
p.
|
article
|
| 205 |
Topic: AS08-Treatment/AS08i-observational studies: REAL WORLD DATA CONFIRMS ACTIVITY OF LUSPATERCEPT IN HIGHER RISK AND HYPOMETHYLATING AGENTS-FAILED PATIENTS WITH MYELODYSPLASTIC SYNDROMES
|
Gong, Y.
|
|
|
128 |
S |
p.
|
article
|
| 206 |
Topic: AS08-Treatment/AS08j-Supportive care, transfusion medicine and MDS, iron overload: MDS CLEARPATH: A WEB-BASED EDUCATIONAL ALGORITHM FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE CANADIAN CONSORTIUM ON MDS (CCMDS); 2023 UPDATE
|
Leitch, H.
|
|
|
128 |
S |
p.
|
article
|
| 207 |
WHAT COULD BE THE FUTURE OF GENETICALLY MODIFIED LYMPHOCYTES IN MDS?
|
Köhl, U.
|
|
|
128 |
S |
p.
|
article
|
Journal description